EMA and heads of national competent authorities discuss consequences of Brexit
Key principles and working methodology established
Although negotiations on the terms of the UK's departure have not yet officially commenced and one cannot prejudge their outcome, work will now start on the basis of the scenario that foresees that the UK will no longer participate in the work of EMA and the European medicines regulatory system as of 30 March 2019.
General principles for workload distribution will include:
- ensuring business continuity;
- maintaining the quality and robustness of the scientific assessment;
- continuing to comply with legal timelines;
- ensuring knowledge retention, either by building on existing knowledge, or through knowledge transfer;
- assuring an easy implementation and medium- and long-term sustainability.
It is expected that all NCAs will contribute to EMA activities as per the capacity and capability of each authority, to ensure an optimised and robust allocation of the workload across the network.
The envisaged working methodology will include a mapping of current and future capacity and expertise in the network and the identification of potential gaps. This could help the network to increase its capacity in selected areas, and would be supported with enhanced training opportunities.
Based on the general principles, EMA, its scientific committees and working parties, together with the NCAs, will now assess the different options for workload distribution. A follow-up meeting will take place on 5 July 2017.
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.